Clinical Trial Search

Primary: Efficacy and Safety of SPN-810 on the Frequency of Impulsive Aggression (IA) Measured by the Impulsive Aggression Diary — -48.16; -47.88; -58.56 percent change of IA…

Primary: Part A: Percentage of Participants With Response to Treatment — 54.2 percentage of participants

Primary: Number of Participants With Serious Adverse Events — 0; 1; 26 Participants

Primary: Mean Change in Children's PROMIS Pediatric Itch Short-Form — -0.3; -0.4 score on a scale — p=0.433

Primary: Progression-free Survival (PFS) — 6.5; 8.4 months

Primary: Change From Baseline in Best-corrected Visual Acuity (BCVA) at Week 52 — 7.3; 10.6; 9.2; 10.5 Scores on a scale — p=<0.001

Primary: The Incidence of Acute Serious Bacterial Infections (SBI) — 0.04; 0; 0.02 Number of events per patient per year

Primary: Percentage of Participants With Combined Response at Week 48 — 2.0; 44.9; 48.0 percentage of participants — p=<0.0001

Primary: Percent Change in Fasting TG From Baseline to Week 12 — -58.89; -22.94 Percent change — p=<0.0001

Primary: The Number of Participants With Treatment Related Select Adverse Events (Grade 3-4 and Grade 5) — 3; 0; 20; 0 Participants

Primary: Number of Participants in Each Treatment Group With a Successful Surface Anesthesia — 153; 152; 14; 19 participants

Primary: Combined Symptom and Medication Score (CSMS) in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo — 7.503; 8.498 Scores on a Scale — p=0.0497

Primary: Immunogenicity Assessments (ADA and Nab) — 3; 2; 3; 0 Participants

Primary: Primary Outcome Measurements to Determine Efficacy of Treatment With CM-AT Versus Placebo for Changes in the Aberrant Behavior Checklist Subscale for Irritability /…

Primary: Number of Participants With First Case of SARS-CoV-2 RT-PCR Positive Symptomatic Illness — 23; 17; 28; 24 Participants — p=0.212